In this episode, we discuss antimicrobial resistance (AMR) priorities, as outlined in the UK National Action Plan (NAP) for AMR, and how microbial genomics can contribute to meeting them in the UK and beyond. Guests Kate Baker, a researcher at the Department of Genetics, University of Cambridge (Cambridge, UK) and Tess Johnson, a bioethicist at the Ethox Centre of the University of Oxford (Oxford, UK) explain the context in which NAPs for AMR are develped in individual countries, and specifically in the UK, following the first release of WHO's AMR Global Action Plan (GAP) in 2015 and its subsequent update adopted at the 79th World Health Assembly in 2026.

They then run us through the outcomes of a stakeholder workshop of the UK Transdisciplinary Antimicrobial Resistance Genomics Network (TARGetAMR) and detail how microbial genomics can be mapped onto all the key priorities of the UK AMR NAP, and highlight key areas that need further development and who the key players in addressing these gaps should be. Finally, they expand their discussion beyond the UK, highlighting how their findings, might or might not be transferrable to other countries. In their conversation, they also mention a TARGetAMR comic, which can be found here https://www.targetamr.org.uk/our-comic/

Click here to read the full article:

https://doi.org/10.1016/j.lanmic.2026.101372

Elisa Pucu speaks with Henriette Svarre Nielsen about their recently published randomised controlled trial, “Vaginal microbiota transplantation for treatment of vaginal dysbiosis without the use of antibiotics: a double-blind, randomised controlled trial in women with vaginal dysbiosis.”

Together, they explore the study’s key findings, its implications for women’s health, and the growing importance of vaginal microbiota transplantation as a research frontier. They also reflect on what lies ahead for this emerging field.

https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00222-8/fulltext

Phoebe Ashley-Norman talks with Zakiul Hassan and Prof Tahmina Shirin about the findings of "Interpreting the natural history and pathogenesis of Nipah virus disease through clinical data, to inform clinical trial design: a systematic review", by Zakiul Hassan and colleagues.

We also discuss Nipah virus disease more broadly, talking about recent phylogenetic findings, diagnostics, therapeutics, vaccines, and ongoing challenges.

Read the systematic review here: https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00223-X/fulltext

We also touched on some past Lancet publications, which you can explore here: https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(23)00361-0/fulltext https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00262-7/fulltext https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00765-5/fulltext https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00707-7/fulltext https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(24)00270-2/fulltext